Medicure
  • Acute Care
    Medicure Focuses On
    Development & Commercialization
    of Cardiovascular Therapeutics

    For the U.S Market


    Learn More
  • Medicure Investments
    medicure is traded
    on TSX Venture (MPH)
    The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).
    Presentation
    Investor Information

Investor News

Latest Financial Reports Corporate Presentation

  Latest News

August 13, 2018
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection.

MAY 1, 2018
Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.

APR 24, 2018
Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018

MAR 28, 2018
Medicure Announces Further Up-Date on PREXXARTAN®

Products

Aggrastat® (tirofiban HCI)

Medicure's leading pharmaceutical product.